Duquesne Family Office’s Acadia Pharmaceuticals ACAD Stock Holding History

Duquesne Family Office’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-74,400	Closed	-$1.78M	–	42
2023 Q2	$1.78M	Hold	74,400	–	–	0.06%	49
2023 Q1	$1.4M	Hold	74,400	–	–	0.06%	45
2022 Q4	$1.18M	Hold	74,400	–	–	0.06%	54
2022 Q3	$1.22M	Hold	74,400	–	–	0.07%	60
2022 Q2	$1.05M	Hold	74,400	–	–	0.08%	40
2022 Q1	$1.8M	Hold	74,400	–	–	0.08%	49
2021 Q4	$1.74M	Hold	74,400	–	–	0.06%	47
2021 Q3	$1.24M	Hold	74,400	–	–	0.04%	47
2021 Q2	$1.81M	Buy	+74,400	New	+$1.68M	0.05%	50

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

FAM

Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return

Duquesne Family Office's ACAD Position: Q3 2023 in Review

Duquesne Family Office sold out of Acadia Pharmaceuticals (ACAD) in Q3 2023, closing a stake of 74,400 shares — an estimated $1.78M sold.

Duquesne Family Office first reported a position in ACAD in Q2 2021 and held it in 9 quarters. The position peaked at $1.81M in Q2 2021. 248 funds tracked by Wall St. Rank hold ACAD as of Q3 2023.

Duquesne Family Office reported no remaining Acadia Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
Duquesne Family Office sold 74,400 Acadia Pharmaceuticals shares in Q3 2023, an estimated $1.78M.
Duquesne Family Office first reported a position in Acadia Pharmaceuticals in Q2 2021 and held it in 9 quarters.
Duquesne Family Office's Acadia Pharmaceuticals position peaked at $1.81M in Q2 2021.
248 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2023.

Based on Duquesne Family Office's 13F filing for Q3 2023, filed 14 Nov 2023.